ReviewEpilepsia2012
Identification of new epilepsy treatments: issues in preclinical methodology.
Review in Epilepsia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 264 citations in OpenAlex.
- A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.eLife · 2015Pooled it
- Eco-friendly MIP-based electrochemical sensor for selective detection of brivaracetam in plasma.Analytical and bioanalytical chemistry · 2026Article
- GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.International journal of molecular sciences · 2026Review
- Integrating fuzzy logic and neural networks with multi-criteria decision-making for intelligent evaluation of drug compound design attributes.Scientific reports · 2026Article
- Harnessing Intelligence from Brain Cells In Vitro.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2025Review
- Spontaneous Seizure Outcomes in Mice Using an Improved Version of the Pilocarpine Model of Temporal Lobe Epilepsy.International journal of molecular sciences · 2025Article
- Article
- Drug treatment alters performance in a neural microphysiological system of information processing.Communications biology · 2025Article
- Automated detection of complex zebrafish seizure behavior at scale.Communications biology · 2025Article
- (+)-Borneol Enhances the Antiseizure Effects of Retigabine by both Pharmacokinetic and Pharmacodynamic Interaction.Neurochemical research · 2025Article
- Article
- Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management.CNS & neurological disorders drug targets · 2025Review
- Adipose-derived stem cell exosomes suppress NLRP3-mediated neuronal pyroptosis to attenuate seizures in a kainic acid-induced temporal lobe epilepsy model.Frontiers in immunology · 2025Article
- Basic and preclinical epilepsy research Scientists' perception of clinical epileptology.Epilepsia · 2025Article
- A Mutual Nexus Between Epilepsy and α-Synuclein: A Puzzle Pathway.Molecular neurobiology · 2024Review
- HyEpiSeiD: a hybrid convolutional neural network and gated recurrent unit model for epileptic seizure detection from electroencephalogram signals.Brain informatics · 2024Article
- Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results.Annals of the Child Neurology Society · 2024Article
- Anti-epileptic and Neuroprotective Effects of Ultra-low Dose NADPH Oxidase Inhibitor Dextromethorphan on Kainic Acid-induced Chronic Temporal Lobe Epilepsy in Rats.Neuroscience bulletin · 2024Article
- Tactile stimulation of young WAG/Rij rats prevents development of depression but not absence epilepsy.Frontiers in behavioral neuroscience · 2024Article
- From bench to bedside: Overview of magnetoencephalography in basic principle, signal processing, source localization and clinical applications.NeuroImage. Clinical · 2024Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 5 countries.
Funding
Abstract
Preclinical research has facilitated the discovery of valuable drugs for the symptomatic treatment of epilepsy. Yet, despite these therapies, seizures are not adequately controlled in a third of all affected individuals, and comorbidities still impose a major burden on quality of life. The introduction of multiple new therapies into clinical use over the past two decades has done little to change this. There is an urgent demand to address the unmet clinical needs for: (1) new symptomatic antiseizure treatments for drug-resistant seizures with improved efficacy/tolerability profiles, (2) disease-modifying treatments that prevent or ameliorate the process of epileptogenesis, and (3) treatments for the common comorbidities that contribute to disability in people with epilepsy. New therapies also need to address the special needs of certain subpopulations, that is, age- or gender-specific treatments. Preclinical development in these treatment areas is complex due to heterogeneity in presentation and etiology, and may need to be formulated with a specific seizure, epilepsy syndrome, or comorbidity in mind. The aim of this report is to provide a framework that will help define future guidelines that improve and standardize the design, reporting, and validation of data across preclinical antiepilepsy therapy development studies targeting drug-resistant seizures, epileptogenesis, and comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.